MUNACHI OKPALA: Open Payments
NPI 1780862821 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 16 payments from 8 companies in 2025. Trend: 2023 $333 · 2024 $449 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| NeuroLogica Corporation, a Samsung Company | 1 | $144 |
| UCB, Inc. | 3 | $81 |
| ARGENX US, INC. | 3 | $60 |
| Novartis Pharmaceuticals Corporation | 3 | $56 |
| Genentech USA, Inc. | 2 | $52 |
| Aucta Pharmaceuticals, Inc. | 2 | $29 |
| C2N Diagnostics, LLC | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
Products named: OmniTom, VYVGART HYTRULO, Ocrevus Zunovo, KESIMPTA, Zilbrysq, Fintepla, Motpoly XR, PRECIVITYAD2.
Industry payments across TX — which companies pay providers there.
